Stock Price Movements, Clinical Study Results, and New Appointments - Research Report on Pfizer, Gilead Sciences, Amgen,

Stock Price Movements, Clinical Study Results, and New Appointments - Research
  Report on Pfizer, Gilead Sciences, Amgen, Celgene, and Insys Therapeutics

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, October 22, 2013

NEW YORK, October 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Gilead Sciences, Inc. (NASDAQ: GILD), Amgen Inc. (NASDAQ:
AMGN), Celgene Corporation (NASDAQ: CELG), and Insys Therapeutics Inc.
(NASDAQ: INSY). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Pfizer Inc. Research Report

On October 17, 2013, Pfizer Inc.'s (Pfizer) stock rose 1.54%, ending the day
at $30.26. Over the previous three trading sessions, shares of Pfizer gained
3.10%, outperforming the S&P 500 which gained 1.35% during the same period.
The Full Research Report on Pfizer Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

Gilead Sciences, Inc. Research Report

On October 16, 2013, Gilead Sciences, Inc. (Gilead) announced three-year
(144-week) efficacy and safety results from two key Phase 3 studies (Studies
102 and 103) evaluating the once-daily single tablet regimen Stribild®
(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg) among treatment naïve patients with HIV-1
infection. According to Gilead, data revealed that after three years of
treatment, Stribild demonstrated comparable efficacy to two standard-of-care
HIV regimens, Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg) in Study 102 and a protease inhibitor-based
regiment of ritonavir boosted atazanavir plus Truvada® (emtricitabine and
tenofovir disoproxil fumarate) in study 103. Commenting on the study results,
Jürgen Rockstroh, MD, Professor of Medicine at University of Bonn, Germany,
said, "In these large-scale clinical trials, Stribild demonstrated high and
durable viral suppression and a favorable safety profile over three years of
therapy. These results support Stribild as an important single-tablet
treatment option for people starting antiretroviral therapy." The Full
Research Report on Gilead Sciences, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/9898_GILD]

--

Amgen Inc. Research Report

On October 16, 2013, Amgen Inc. (Amgen) announced the appointment of Greg C.
Garland, Chairman, President, and CEO of Phillips 66, to the Company's Board
of Directors. The Company said that Garland will serve on the Governance and
Nominating Committee and the Audit Committee of the Board. Commenting on the
appointment, Robert A. Bradway, Chairman and CEO of Amgen, said, "We are
pleased to welcome Greg Garland to the Amgen Board. In addition to his
leadership experiences as a chief executive officer, Greg brings more than 30
years of international experience in a highly regulated industry. At a time
when Amgen is expanding its global presence to serve more patients, we look
forward to Greg's contributions to the Board." The Full Research Report on
Amgen Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e96b_AMGN]

--

Celgene Corporation Research Report

On October 16, 2013, Celgene International Sàrl, a wholly owned subsidiary of
Celgene Corporation (Celgene), announced the results of MPACT (Metastatic
Pancreatic Adenocarcinoma Clinical Trial) phase III clinical trial of
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)
(albumin-bound) in combination with gemcitabine were published online in the
October 16th edition of the New England Journal of Medicine. The Company
informed that MPACT study is a Celgene-sponsored, open-label, randomized,
study of 861 previously untreated patients with metastatic pancreatic cancer
at 151 community and academic centers from 11 countries in North America.
Markus Renschler, M.D., Corporate Vice President, Global Head of Hematology
and Oncology Medical Affairs at Celgene, said, "The peer-reviewed publication
of the MPACT results in the New England Journal of Medicine further validates
the importance of this treatment regimen. These results led to the U.S. Food
and Drug Administration's approval of ABRAXANE for the first-line treatment of
patients with metastatic adenocarcinoma of the pancreas, in combination with
gemcitabine." The Full Research Report on Celgene Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7f47_CELG]

--

Insys Therapeutics Inc. Research Report

On October 17, 2013, Insys Therapeutics Inc.'s (Insys) stock rose 12.68%,
ending the day at $42.30. Over the previous three trading sessions, shares of
Insys have gained 6.66%, outperforming the Nasdaq Composite which gained 1.25%
during the same period. The Full Research Report on Insys Therapeutics Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/aabc_RCPT]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.